carrito Compra

(0 Productos)

Gastos de envío GRATIS

Solo para España


  1. Autor:

    Marquez Medina

  2. Isbn:


  3. Páginas:


  4. Año:


  5. Edición:


  6. Idioma:


  7. Disponibilidad:

    De 2 a 3 Semanas

Precio s/iva:

175.00 €

166,25  €

Lung cancer is the most common and most lethal malignancy worldwide, causing 1.4 million diseases every year. Half of non-small cell lung cancers (NSCLC) are diagnosed at such an advanced stage that a cure cannot be considered a realistic aim, and over 75% of cases selected for a curative treatment eventually relapse within five years. The 5-year overall survival rates are less than 20% for NSCLC patients. As a disease, NSCLC demands our maximum abilities as researchers, physicians, and care-givers, and a continuous updating of our knowledge.

Conventional chemotherapy for advanced NSCLC does not provide a great long-term benefit in terms of survival. Accordingly, a different therapeutic approach has to be explored. The human epidermal growth factor family of surface receptors (HER) became a critical target to be investigated.

The epidermal growth factor receptor (EGFR) is overexpressed in over 80% of non-small cell lung cancer. The presence of sensitizing conformational mutations in the EGFR increases the efficacy of modern tyrosine kinase inhibitors against its inner portion (EGFR-TKI). The EGFR-TKIs greatly prolong disease-free survival of those patients harboring sensitizing EGFR mutations, and have been suggested as an essential tool in the therapeutic repertoire.

This volume aims to serve as an updated compendium of biology and applications of anti-EGFR therapies, and offers a look at the future of anti-HER therapy in lung cancer.

This volume exhaustively reviews and discusses: 1) the nature and significance of activating EGFR mutations, and those clinical and pathological phenomena related to HER alterations 2) the most common laboratory methodologies to study EGFR, and the future of HER analysis 3) the right time to analyze EGFR mutations and evolutionary changes in the HER 4) EGFR-TKI application in unselected and selected NSCLC patients 5) upcoming anti-HER therapies 6) the eventual role of anti-HER therapies in early NSCLC 7) mechanisms of acquired resistance to anti-HER therapies, and experimental and conventional strategies to bypass them 8) the application of anti-HER therapies in other malignancies.

This book is an indispensable handbook for all those specialists devoted to the diagnosis and management of lung cancer.

Chapter 1. Lung Cancer I. Epidemiology, Pathology and Diagnosis. Tissue Sampling
(Amaia Ojanguren, Miriam Barrecheguren and Iñigo Ojanguren, Arnau of Vilanova University Hospital of Lleida, Spain and others)pp.1-16

Chapter 2. Lung Cancer II. Conventional Treatment for Advanced Non-Small Cell Lung Cancer
(Oscar Juan-Vidal and Corina Escoin, La Fe University Hospital of Valencia, Spain)pp.17-42

Chapter 3. Biology I. Human Epidermal Growth Factor Receptors in Health and Tumor Cells
(m. Ángeles Montero-Fernández, Royal Brompton and Harefield Trust of London, United Kingdom)pp.43-54

Chapter 4. Biology II. Etiology and Histology of Lung Cancer According to the Presence of Alterations in the Human Epidermal Growth Factor Family of Receptors
(Diego Márquez-Medina, Arnau de Vilanova University Hospital of Lleida, Spain)pp.55-70

Chapter 5. Laboratory I. Analysis of Human Epidermal Growth Factor Receptors: Conventional Analysis
(Beatriz Bellosillo and Luz Martínez-Avilés, Hospital del Mar University Hospital of Barcelona, Spain)pp.71-90

Chapter 6. Laboratory II. Experimental Analysis of Human Epidermal Growth Factor Receptors
(Javier Hernández-Losa, Vall d""Ebron University Hospital of Barcelona, Spain)pp.91-106

Chapter 7. Timing I. Dynamic Analysis of Human Epidermal Growth Factor Receptors. Role of Rebiopsy
(Santiago Viteri and Alejandro Martínez-Bueno, Instituto Rosell de Oncología of Barcelona, Spain)pp.107-114

Chapter 8. Timing II. Appropriate Time to Determine the Presence of EGFR Mutation and Sequence of Treatment
(Teresa Morán, Enric Carcereny, María de los Llanos Gil, Laia Vilà, Alberto Indacochea and Jordi Remón, Catalan Institut of Oncology of Badalona, Spain)pp.115-130

Chapter 9. Treatment I. Treatment of Unselected Patients with Epidermal Growth Factor Tyrosine Kinase Inhibitors
(Edurne Arriola, Álvaro Taus and David Casadevall, Hospital del Mar University Hospital of Barcelona, Spain)pp.131-152

Chapter 10. Treatment II. Treatment of Selected Non-Small Cell Lung Cancer Patients
(Ramón Palmero, Catalan Institut of Oncology of L""Hospitalet, Spain)pp.153-162

Chapter 11. Future I. Still Unapproved Drugs
(Rosario García-Campleo, Joaquín Mosquera and Aurea Molina, A Coruña University Hospital, Spain)pp.163-178

Chapter 12. Future II. Targeted Therapies in Early-Stage Non-Small Cell Lung Cancer
(Elsa Dalmau Pórtulas and Marta Ferrer Cardona, Parc Tauli University Hospital of Sabadell, Spain)pp.179-190

Chapter 13. Resistance I. Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer
(Jordi Remón and Pilar Lianes, Hospital of Mataró, Spain)pp.191-210

Chapter 14. Resistance II. Conventional Salvage Therapies for the Resistance to Anti-Human Epidermal Growth Factor Receptor Treatments
(Diego Márquez-Medina, Arnau de Vilanova University Hospital of Lleida, Spain)pp.211-234

Chapter 15. Other Malignancies I. Breast Cancer
(E. Aguirre, S. Morales and A. Llombart, Arnau de Vilanova University Hospital of Lleida, Spain)pp.235-252

Chapter 16. Other Malignancies II. Gynaecological and Head and Neck Cancer
(Yolanda García García, Estefania García Pérez and Julio Ocaña Rojas, Parc Taulí University Hospital of Sabadell, Spain)pp.253-274

Chapter 17. Other Malignancies III. Digestive Tract
(Teresa Taberner-Bonastre, Instituto Madrileño de Oncología of Madrid Spain)pp.275-286

Libreria Médica Berri 2024 ®